Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
583 Views
MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors
MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...
626 Views
MabPharm (迈博医药) IPO: Thoughts on Valuation (Part 2)
MabPharm is expected to launch its IPOsoon. In our previous insights (links provided below), we provided a detailed analysis of the company's core...
846 Views
MabPharma (迈博医药) IPO: Assembled for a Trade?
MabPharma, backed by Chinese private equity investor CDH, is seeking to list in Hong Kong. In this insight, we will discuss the following...
817 Views